PCT (procalcitonin)

A biomarker to aid in the diagnosis of sepsis

Request more info about biomarkers
I would like to know more about Radiometer biomarkers

Infection (PCT, CRP) Myocardial infarction (TnI, CKBM, Myo) Heart failure (NT-proBNP) Pregnancy (ßhCG) Venous thromboembolism (D-dimer)

Contact Info
Name

Job function

E-mail

Phone number

I agree to receive news and information from Radiometer. I understand that I can opt-out any time. Please contact me by phone

Workplace Details
Hospital / Institution

Department

State

ZipCode

Country

Message

By submitting this form, I acknowledge that I have reviewed and understood the data privacy notice.

All fields must be filled!
See more products

Fast results
Early detection of sepsis
Better monitoring of disease progression

PCT testing in the emergency department

Many patients arrive at the emergency department with a local infection or, in some cases, develop an infection after major trauma or surgery.

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [1]. Sepsis is the number 1 cause of death in hospitals [2].

Sepsis can be difficult to identify, particularly in the initial stages, and it presents a considerable diagnostic challenge to the emergency department and intensive care clinicians.

Procalcitonin (PCT) is released in larger amounts in response to infection, thereby acting as a risk indicator for sepsis.

Immunoassay products and solutions

CRP (C-reactive protein)

D-dimer

NT-proBNP

Procalcitonin (PCT)

Troponin I

CRP (C-reactive protein)

PCT - a biomarker to aid in the diagnosis of sepsis

Procalcitonin (PCT) is a 116–amino acid polypeptide prohormone of calcitonin.

PCT is synthesised primarily by the C-cells of the thyroid gland, and to a lesser extent in the neuroendocrine tissue of other organs such as the lungs and intestines. Normal procalcitonin levels in the blood are very low [3].

However, production can be stimulated in almost every organ by inflammatory cytokines and especially bacterial endotoxins present e.g., during sepsis, causing high amounts of PCT to be released in the blood. This allows PCT levels to be used as a biomarker of sepsis. The higher the level of PCT, the greater the likelihood of systemic infection and sepsis [3].

More information on PCT in the diagnosis of sepsis

The mortality and morbidity rates associated with sepsis remain higher than any other infection-related condition, despite strict guidelines for the implementation of early and effective therapies which have improved the chance of survival [4].

Radiometer’s rapid, acute care AQT90 FLEX PCT test, an in vitro diagnostic assay for the quantitative determination of PCT in EDTA or lithium-heparin whole blood or plasma specimens, is an important tool for acute and intensive care professionals, aiding the early detection of sepsis. This enables clinicians to start antibiotic treatment undelayed.

PCT has the potential advantage of earlier disease diagnosis and better monitoring of disease progression. Early diagnosis and treatment are critical for survival rates [5].

Testing PCT on the AQT90 FLEX analyser

Radiometer’s AQT90 FLEX immunoassay analyser is a benchtop analyser that brings rapid biomarker assessment capabilities right to the patient’s bedside. The AQT90 FLEX delivers PCT results in less than 21 minutes, aiding the clinicians in the work-up of critically ill patients at risk for sepsis [6].

Its closed tube system makes PCT testing easy: the operator simply inserts the sample tube into the tube holder in the sample port and the analyser performs all assay steps automatically. There is no need for sample preparation.

Learn more about the AQT90 FLEX analyser

Key benefits of PCT on the AQT90 FLEX analyser

No blood exposure: closed system
No sample or assay preparation
Specimen types: Venous whole blood and plasma samples
PCT assays in general have shown excellent agreement with blood culture
High correlation with other commercially available PCT assays

PCT assay specifics

Turnaround time:

21 min.

CV % (plasma): Within-lab CV % at conc. 0.092 μg/L: 12.5%

95th percentile*: < 0.12 μg/L for whole blood and 0.087 μg/L for plasma

Traceability: Harmonised to correlate with results of the B∙R∙A∙H∙M∙S PCT® sensitive KRYPTOR® assay

* These values should only be used as an example. Each laboratory should establish its own decision threshold level.

Note on trademarks

B·R·A·H·M·S PCT® and B·R·A·H·M·S® are registered trademarks of B·R·A·H·M·S GmbH; KRYPTOR® is a registered trademark of Cisbio Bioassays; all other trademarks belong to their respective owners.

References

1. Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016
2. Rudd et al. Global, regional, and national sepsis incidence and mortality, 1990 -2017: analysis for the Global Burden of Disease Study. The Lancet Volume 395, Issue 10219, 18 -24 January 2020; 200-211.
3. Sartelli M, et al. The role of procalcitonin inreducing antibiotics across the surgical pathway. World Journal of Emergency Surgery. 2021
4. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010
5. Riedel S, et al. Procalcitonin as a Marker for the Detection of Bacteremia and Sepsis in the Emergency Department. Am J Clin Pathol 2011
6. Li et al. Determining procalcitonin at point-of-care; A method comparison study of four commercial PCT assays. Practical Laboratory Medicine 2021; 25.

Cookies are used on this website

Use of cookies

Don't show this message again

Radiometer is using Microsoft AZURE Active Directory to authenticate users

Radiometer uses Azure AD to provide our customers and partners secure access to documents, resources, and other services on our customer portal.

If your organization is already using Azure AD you can use the same credentials to access Radiometer's customer portal.

Key benefits

Allow the use of existing Active Directory credentials
Single-sign on experience
Use same credentials to access future services

Request access

You will receive an invitation to access our services via e-mail when your request has been approved.

When you accept the invitation, and your organization is already using AZURE AD, you can use the same credentials to access Radiometer's customer portal. Otherwise, a one-time password will be sent via e-mail to sign in.

Effective Date January 20th, 2023 (last updated January 20th, 2023)

ABOUT THIS POLICY

Radiometer values your privacy and the protection of your personal data. This policy (“Policy”) explains how Radiometer its affiliates, subsidiaries or related companies, a full list of which can be located here (together, “Radiometer,”, “our”, “us,” or “we”), collects, uses, shares, transfers and processes data collected from or about you.

“Personal Data” is any information that can be used to directly or indirectly identify an individual or that can be reasonably expected to link to an individual. This can include items such as name, address, telephone number, credit card details, email address, ID number, Internet Protocol (“IP”) address of an electronic device used by an individual, or other identifying code (even absent of other identifying information). Statistical and non-identifiable metric data are not considered Personal Data.

The Radiometer subsidiary, affiliate or related company with which you interact is, where applicable, the data controller (or equivalent under applicable law) responsible for the processing of your Personal Data. You can find a list of the relevant legal entities that act as data controllers in Appendix 1 to this Policy.

SCOPE

This Policy describes the types of Personal Data that we may collect, process or disclose about you and how you may govern this processing by exercising applicable legal rights. This Policy applies to both online and offline information collection, including your use of websites or subdomains operated by us, any mobile applications, when we provide products and/or services to you or notify you about prospective items of interest and in other situations where you interact with us in-person, by telephone or by mail where this Policy is posted or referenced.

There may be occasion where you have been provided with a circumstance-specific privacy notice that is separate from this policy, such as privacy notices for specific activities such as Recruitment. To the extent you were provided with a different notice, those notices apply and govern our interactions with you. If you provide Personal Data about parties other than yourself, you are responsible for ensuring their knowledge of how we will process their personal data, and, where applicable, obtaining any necessary consents required in advance.